Compare Crowdstrike Holdings Inc (CRWD) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs GeneDx Holdings Corp — how do they compare? Crowdstrike Holdings Inc trades at $275.04 (market cap $269.31B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Crowdstrike Holdings Inc is far larger — about 133.3× GeneDx Holdings Corp's market cap, and Crowdstrike Holdings Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crowdstrike Holdings Inc for 97 Days and GeneDx Holdings Corp for 19 Days on average.
| CRWD | WGS | |
|---|---|---|
Market Cap | $269.31B | $2.02B |
Volume | 9,381,560 | 734,640 |
Sector | Technology | Health |
52-Week High | $278.86 | $167.51 |
52-Week Low | $87.56 | $34.51 |
Typical Hold Time | 97 Days | 19 Days |
Enterprise Value | $265.11B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $263.01, down 0.92% on the day but near its 52-week high of $267.69. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings expectations in recent quarters. Revenue growth remains robust, reaching $3.95 billion in 2025, though profitability metrics show modest net income margins. Analyst sentiment is overwhelmingly positive with 76% buy ratings and a consensus price target of $235.74.
CrowdStrike presents a compelling growth story with strong revenue expansion and AI-driven cybersecurity demand, but faces valuation concerns with elevated P/S and P/B ratios. The company's integration with OpenAI Marketplace and identity business growth provide catalysts, while competitive pressures and execution risks remain key considerations for investors.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
